{"id":"https://openalex.org/W2000640395","doi":"https://doi.org/10.1158/1538-7445.am10-2671","title":"Abstract 2671: Structural analysis of the inhibitory mechanism of AP24534, a pan-BCR-ABL inhibitor overriding the T315I gatekeeper mutation","display_name":"Abstract 2671: Structural analysis of the inhibitory mechanism of AP24534, a pan-BCR-ABL inhibitor overriding the T315I gatekeeper mutation","publication_year":2010,"publication_date":"2010-04-01","ids":{"openalex":"https://openalex.org/W2000640395","doi":"https://doi.org/10.1158/1538-7445.am10-2671","mag":"2000640395"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am10-2671","doi":"https://doi.org/10.1158/1538-7445.am10-2671","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am10-2671","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004723852","display_name":"Xiaotian Zhu","orcid":"https://orcid.org/0000-0002-6982-1486","observed_orcids":["https://orcid.org/0000-0002-6982-1486"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaotian Zhu","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tianjun Zhou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tianjun Zhou","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028196907","display_name":"William C. Shakespeare","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William C. Shakespeare","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004778927","display_name":"Wei\u2010Sheng Huang","orcid":"https://orcid.org/0000-0002-9614-1224","observed_orcids":["https://orcid.org/0000-0002-9614-1224"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei-Sheng Huang","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043782238","display_name":"Lois Commodore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lois Commodore","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090144335","display_name":"Chester A. Metcalf","orcid":"https://orcid.org/0000-0002-0761-1125","observed_orcids":["https://orcid.org/0000-0002-0761-1125"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chester A. Metcalf","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100428930","display_name":"Yihan Wang","orcid":"https://orcid.org/0009-0003-4447-2536","observed_orcids":["https://orcid.org/0009-0003-4447-2536","https://orcid.org/0000-0001-6032-710X"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yihan Wang","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030521196","display_name":"Mathew Thomas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mathew Thomas","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106035955","display_name":"Raji Sundaramoorthi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raji Sundaramoorthi","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102505391","display_name":"Dong Zou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dong Zou","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113494503","display_name":"Tomi K. Sawyer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tomi K. Sawyer","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109928146","display_name":"Tim Clackson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tim Clackson","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008040654","display_name":"David C. Dalgarno","orcid":"https://orcid.org/0009-0003-1081-1608","observed_orcids":["https://orcid.org/0009-0003-1081-1608"]},"institutions":[{"id":"https://openalex.org/I4387156154","display_name":"ARIAD Pharmaceuticals (United States)","ror":"https://ror.org/01dwtyk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I4387156154","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Dalgarno","raw_affiliation_strings":["1Ariad Pharmaceuticals Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Ariad Pharmaceuticals Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4387156154"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4387156154"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"70","issue":"8_Supplement","first_page":"2671","last_page":"2671"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bcr-abl","display_name":"BCR-ABL","score":0.7429999709129333},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9399999976158142},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.9589999914169312},{"id":"https://openalex.org/keywords/abl-kinase-inhibitors","display_name":"ABL kinase inhibitors","score":0.800000011920929},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.8209999799728394},{"id":"https://openalex.org/keywords/crystal-structure","display_name":"crystal structure","score":0.6110000014305115},{"id":"https://openalex.org/keywords/point-mutations","display_name":"point mutations","score":0.5680000185966492},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6679999828338623}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.8319199085235596},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.8203376531600952},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.7257623076438904},{"id":"https://openalex.org/C125418893","wikidata":"https://www.wikidata.org/wiki/Q587961","display_name":"ABL","level":4,"score":0.623859703540802},{"id":"https://openalex.org/C176944494","wikidata":"https://www.wikidata.org/wiki/Q1415380","display_name":"Point mutation","level":4,"score":0.6188364028930664},{"id":"https://openalex.org/C32619005","wikidata":"https://www.wikidata.org/wiki/Q24768234","display_name":"Protein kinase domain","level":4,"score":0.5513632893562317},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5055954456329346},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.48347193002700806},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.48318353295326233},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.4494117498397827},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.44022977352142334},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.32573479413986206},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.23902741074562073},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.23858729004859924},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.13629576563835144},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.07196244597434998}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am10-2671","doi":"https://doi.org/10.1158/1538-7445.am10-2671","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am10-2671","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.550000011920929,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1992121712","https://openalex.org/W2763572665","https://openalex.org/W2890336441","https://openalex.org/W2230151041","https://openalex.org/W2155615242","https://openalex.org/W2314058894","https://openalex.org/W2163329109","https://openalex.org/W2150962457","https://openalex.org/W2056917031","https://openalex.org/W2025422981"],"abstract_inverted_index":{"Abstract":[0],"Although":[1],"durable":[2],"response":[3],"in":[4,19,124,136,167,212,217,249,262,268],"many":[5],"chronic":[6],"myeloid":[7],"leukemia":[8],"(CML)":[9],"patients":[10,269],"can":[11,28,245],"be":[12],"achieved":[13],"by":[14],"imatinib":[15,49],"treatment,":[16],"point":[17,236],"mutations":[18],"the":[20,24,38,57,75,91,120,127,142,147,159,163,170,180,196,208,229,288,293],"kinase":[21,43],"domain":[22],"of":[23,97,104,119,157,191,204,207,232,234,287,292],"BCR-ABL":[25],"fusion":[26],"protein":[27],"lead":[29],"to":[30,134,225,238,241],"drug":[31],"resistance":[32,248],"and":[33,36,78,107,113,162,182,194,227,240,272,275],"relapse.":[34],"Nilotinib":[35],"dasatinib,":[37],"two":[39],"second":[40],"generation":[41],"Abl":[42,123,135],"inhibitors,":[44],"are":[45],"active":[46],"against":[47,179],"most":[48],"resistant":[50,273],"mutants":[51,81,186,237],"with":[52,126,141,169,270],"a":[53,63,70,86,102,137,214,263],"few":[54],"exceptions,":[55],"particularly":[56],"T315I":[58,76,121,164,181],"gatekeeper":[59],"residue":[60,150],"mutation.":[61],"Using":[62],"structure-based":[64],"approach":[65],"we":[66,99],"have":[67,100],"identified":[68],"AP24534,":[69,98,239],"molecule":[71],"that":[72,131,175,201],"potently":[73],"inhibits":[74],"mutant":[77,122,165],"all":[79],"other":[80,183,276],"tested,":[82],"thus":[83],"acting":[84],"as":[85],"pan-BCR-ABL":[87],"inhibitor.":[88],"To":[89],"elucidate":[90],"basis":[92],"for":[93,296],"this":[94],"unique":[95],"profile":[96],"used":[101],"combination":[103],"X-ray":[105,155],"crystallographic":[106],"structure-activity":[108],"relationship":[109],"analysis":[110,222],"on":[111],"AP24534":[112,132,176,244,257],"its":[114],"analogs.":[115],"The":[116,154],"crystal":[117],"structure":[118],"complex":[125],"inhibitor":[128],"clearly":[129],"demonstrates":[130],"binds":[133],"DFG-out":[138],"binding":[139,198,209,218],"mode":[140],"ethynyl":[143],"chemical":[144],"moiety":[145],"skirting":[146],"mutated":[148],"gate-keeper":[149],"avoiding":[151],"steric":[152],"clashes.":[153],"co-structures":[156],"both":[158],"wild":[160],"type":[161],"Abl,":[166],"conjunction":[168],"SAR":[171],"analysis,":[172],"further":[173],"reveal":[174],"retains":[177],"potency":[178],"imatinib-resistant":[184],"ABL":[185,235],"through":[187],"optimized":[188],"multiple":[189],"points":[190],"contact,":[192],"balancing":[193],"distributing":[195],"overall":[197],"affinity":[199],"so":[200],"mutation-based":[202],"disruption":[203],"one":[205],"facet":[206],"network":[210],"results":[211],"only":[213],"slight":[215],"reduction":[216],"affinity.":[219],"Our":[220],"structural":[221],"enables":[223],"us":[224],"predict":[226],"rationalize":[228],"different":[230],"degree":[231],"sensitivity":[233],"understand":[242],"how":[243],"completely":[246],"abrogate":[247],"cell-based":[250],"mutagenesis":[251],"screens":[252],"at":[253],"relatively":[254],"low":[255],"concentrations.":[256],"is":[258],"currently":[259],"being":[260],"investigated":[261],"Phase":[264],"I":[265],"clinical":[266],"trial":[267],"refractory":[271],"CML":[274],"hematological":[277],"malignancies.":[278],"Citation":[279],"Format:":[280],"{Authors}.":[281],"{Abstract":[282],"title}":[283],"[abstract].":[284],"In:":[285],"Proceedings":[286],"101st":[289],"Annual":[290],"Meeting":[291],"American":[294],"Association":[295],"Cancer":[297,307],"Research;":[298],"2010":[299],"Apr":[300],"17-21;":[301],"Washington,":[302],"DC.":[303],"Philadelphia":[304],"(PA):":[305],"AACR;":[306],"Res":[308],"2010;70(8":[309],"Suppl):Abstract":[310],"nr":[311],"2671.":[312]},"counts_by_year":[],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2025-10-10T00:00:00"}